You are here

ubrogepant

AbbVie’s Migraine Drug Ubrelvy Scores Victory in Phase III Study

BioSpace

Fri, 11/17/23 - 10:00 am

clinical trials

In final report, ICER appears to have a change of heart on new acute migraine therapies

Endpoints

Tue, 02/25/20 - 10:40 am

Allergan scores year-end FDA nod for CGRP migraine med Ubrelvy, plans early 2020 launch

Fierce Pharma

Mon, 12/23/19 - 11:56 pm

3 Biotechs Facing FDA Approvals by Year's End

Motley Fool

Mon, 12/9/19 - 09:45 am

Intra-Cellular Therapies

Go or no go? Vascepa’s finale and Allergan's pain relief

EP Vantage

Mon, 12/2/19 - 10:37 am

Before 2019 closes, the FDA has 3 key approval decisions to make

Biopharma Dive

Wed, 11/27/19 - 12:43 pm

Intra-Cellular Therapeutics

bipolar disorder

Allergan builds case for migraine drug ubrogepant as FDA verdict nears

Pharmaforum

Wed, 11/20/19 - 10:04 am

Allergan's NDA for Migraine Med With Novel Mechanism of Action Accepted by FDA

BioSpace

Tue, 03/19/19 - 10:29 am

Eyeing blockbuster migraine market, Allergan unloads second set of positive PhIII results for ubrogepant

Endpoints

Fri, 04/27/18 - 10:09 am

clinical trials

Will Allergan cannibalize Botox with ubrogepant?

Biopharma Dive

Fri, 02/9/18 - 10:06 am

As Migraine Races Heat Up, Allergan Touts New Data for Headache Pill

Xconomy

Tue, 02/6/18 - 09:27 am